215 related articles for article (PubMed ID: 8963784)
1. [Immunosuppression and the problems in homologous bone marrow transplantation].
Yabe H; Kato S
Nihon Rinsho Meneki Gakkai Kaishi; 1995 Dec; 18(6):681-2. PubMed ID: 8963784
[No Abstract] [Full Text] [Related]
2. Role of immunosuppressive drugs for prevention of graft-v-host disease after human HLA matched bone marrow transplantation.
Gluckman E; Devergie A; Lokiec F; Traineau R; Cosset JM; Lemercier N; Varrin F; Cavazzana M; de Castro H; Meletis J
Transplant Proc; 1987 Dec; 19(6 Suppl 7):61-5. PubMed ID: 3321648
[No Abstract] [Full Text] [Related]
3. Cyclosporine does not prevent in vivo expression of T cell activation antigens following allogeneic bone marrow transplantation.
Forman SJ; Gallagher MT; Zaia JA; Wright C; Blume KG
Transplantation; 1984 Feb; 37(2):219-20. PubMed ID: 6420961
[No Abstract] [Full Text] [Related]
4. Regeneration of genetically restricted immune functions after human bone marrow transplantation: influence of four different strategies for graft-v-host disease prophylaxis.
Donnenberg AD; Hess AD; Duff SC; Bright EC; Noga SJ; Rowley SD; Saral R; Santos GW
Transplant Proc; 1987 Dec; 19(6 Suppl 7):144-52. PubMed ID: 3321641
[No Abstract] [Full Text] [Related]
5. The problems and practice of bone marrow transplantation in man: the severe combined immunodeficiency syndrome as the ideal model.
Levey RH
Transplant Proc; 1972 Dec; 4(4):565-6. PubMed ID: 4405148
[No Abstract] [Full Text] [Related]
6. Lymphocyte reconstitution after allogeneic bone marrow transplantation in a previously thymectomized patient--no evidence of extrathymic T-cell maturation.
Giebel S; Dziaczkowska J; Wysoczanska B; Wojnar J; Krawczyk-Kulis M; Lange A; Holowiecki J
Bone Marrow Transplant; 2007 Oct; 40(7):705-6. PubMed ID: 17680024
[No Abstract] [Full Text] [Related]
7. Cyclosporin a: a new era in organ transplantation.
DeBakey ME
Compr Ther; 1984 Feb; 10(2):7-15. PubMed ID: 6368108
[No Abstract] [Full Text] [Related]
8. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies.
O'Donnell PV; Jones RJ; Vogelsang GB; Seber A; Ambinder RF; Flinn I; Miller C; Marcellus DC; Griffin C; Abrams R; Braine HG; Grever M; Hess AD; Piantadosi S; Noga SJ
Bone Marrow Transplant; 1998 Nov; 22(10):947-55. PubMed ID: 9849691
[TBL] [Abstract][Full Text] [Related]
9. [Immunologic problems in allogenic and autologous bone marrow transplantation].
Schwenke H; Helbig W; Kubel M; Schultze W
Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(2):217-23. PubMed ID: 6208106
[No Abstract] [Full Text] [Related]
10. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
11. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
12. Modulation of graft-versus-host disease: role of regulatory T lymphocytes.
Hess AD
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):13-21. PubMed ID: 16399597
[TBL] [Abstract][Full Text] [Related]
13. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
14. Immunoregulation rather than immunosuppression for prevention and treatment of autoimmune disorders.
Slavin S
Transplant Proc; 1996 Dec; 28(6):3021-2. PubMed ID: 8962172
[No Abstract] [Full Text] [Related]
15. Safe and efficacious allogeneic bone marrow transplantation for nonmalignant disorders using partial T cell depletion and no posttransplantation graft-versus-host-disease prophylaxis.
Elhasid R; Arush MB; Zaidman I; Leiba R; Barak AB; Postovsky S; Haddad N; Katz T; Pollack S; Sami I; Gidoni O; Rubin D; Mandel H; Attias D; Reisner Y; Etzioni A; Rowe JM
Biol Blood Marrow Transplant; 2007 Mar; 13(3):329-38. PubMed ID: 17317586
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine. Bone marrow transplantation.
Transplant Proc; 1983 Dec; 15(4 Suppl 1-2):2613-37. PubMed ID: 6364508
[No Abstract] [Full Text] [Related]
17. Induction of tolerance with cyclosporin A.
Tutschka PJ
Prog Clin Biol Res; 1986; 224():209-26. PubMed ID: 2948193
[No Abstract] [Full Text] [Related]
18. Bone marrow transplantation: an option for children with acute leukemia.
Stream P; Harrington E; Clark M
Cancer Nurs; 1980 Jun; 3(3):195-9. PubMed ID: 6991098
[No Abstract] [Full Text] [Related]
19. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporine. Experimental transplantation. Bone marrow.
Transplant Proc; 1983 Dec; 15(4 Suppl 1-2):3035-49. PubMed ID: 6364512
[No Abstract] [Full Text] [Related]
[Next] [New Search]
